Outcome of patients with advanced MDS given allogeneic HSCT. Probability of EFS according to the type of donor (HLA-identical sibling, 10/10 allelic matched and 9/10 allelic matched unrelated volunteer) used in patients with MDS-EB given an allograft after a myeloablative conditioning regimen that included busulfan, cyclophosphamide, and melphalan. Data from the EWOG-MDS registry. E, events observed; N, number of patients at risk; n.s., not significant.